Abstract
Endovascular renal artery stent therapy for atherosclerotic renal artery stenosis (RAS) is associated with excellent acute technical success, low complication rates and acceptable long-term patency. However, the clinical benefits to patients of renal artery stenting remain uncertain. To facilitate debate regarding the treatment of RAS, we need to understand the epidemiology, basic physiology and clinical consequences of renal artery stenosis. We must attempt to determine which patients are likely to benefit from renal artery stenting, assess the nuances of the percutaneous procedure and review the current literature pertaining to renal artery stenting.
MeSH terms
-
Abciximab
-
Angioplasty, Balloon
-
Antibodies, Monoclonal / therapeutic use
-
Atherosclerosis / complications
-
Clinical Trials as Topic
-
Disease Progression
-
Humans
-
Hypertension / epidemiology
-
Immunoglobulin Fab Fragments / therapeutic use
-
Patient Selection
-
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
-
Practice Guidelines as Topic
-
Recurrence
-
Renal Artery Obstruction / epidemiology
-
Renal Artery Obstruction / etiology
-
Renal Artery Obstruction / physiopathology
-
Renal Artery Obstruction / surgery*
-
Severity of Illness Index
-
Stents
-
Treatment Outcome
-
Vascular Patency
Substances
-
Antibodies, Monoclonal
-
Immunoglobulin Fab Fragments
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Abciximab